To investigate the effects of cisapride on the gastrointestinal symptoms, gastrointestinal hormone-related indicators and renal function in patients with chronic renal failure.

A total of 109 patients with chronic renal failure admitted to our department from June 2018 to March 2020 were selected as the research subjects, and grouped according to the treatments strategies. The 54 patients in the control group were given conventional treatment, and another 55 patients in the observation group were given cisapride additional to the conventional treatment. The gastrointestinal symptoms, clinical efficacy, gastrointestinal hormones and renal function of the two groups of patients were observed.

The total effective rate of the observation group was higher than that of the control group (94.55% vs 81.48%, P<0.05). The scores of symptoms such as nausea and bloating in the observation group were lower than those in the control group (P<0.05). In the observation group, there were no significant changes in gastrin (GAS), serum somatostatin (SS) and vasoactive intestinal peptide (VIP) (P>0.05), while the motilin (MOT) level was significantly lower than that in the control group (P<0.05). The levels of serum creatinine (Scr), endogenous creatinine clearance rate (Ccr), and blood urea nitrogen (BUN) in the observation group had no significant changes when compared with the control group (P>0.05).

Cisapride can improve clinical symptoms and the MOT level by promoting gastrointestinal movement, and enhance clinical efficacy without effecting the renal function of the patients.

Cisapride; Chronic renal failure; Gastrointestinal hormones; Gastrointestinal symptoms; Renal function